Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD), administered intravenously without a psychotherapeutic component. In these settings, ketamine's psychedelic effects are viewed as undesirable "side effects." In contrast, we believe ketamine can benefit patients with a wide variety of diagnoses when administered with psychotherapy and using its psychedelic properties without need for intravenous (IV) access. Its proven safety over decades of use makes it ideal for office and supervised at-home use. The unique experience that ketamine facilitates with its biological, experiential, and psychological impacts has been tailored to optimize office-based treatment evolving into a method that we call Ketamine Assisted Psychotherapy (KAP). This article is the first to explore KAP within an analytical framework examining three distinct practices that use similar methods. Here, we present demographic and outcome data from 235 patients. Our findings suggest that KAP is an effective method for decreasing depression and anxiety in a private practice setting, especially for older patients and those with severe symptom burden.
Keywords: Depression; PTSD; ketamine; psychedelic psychotherapy; psychedelics; psychotherapy.
Reviewing the Potential of Psychedelics for the Treatment of PTSD.Int J Neuropsychopharmacol. 2020 Mar 14:pyaa018. doi: 10.1093/ijnp/pyaa018. Online ahead of print. Int J Neuropsychopharmacol. 2020. PMID: 32170326
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up.J Subst Abuse Treat. 2002 Dec;23(4):273-83. doi: 10.1016/s0740-5472(02)00275-1. J Subst Abuse Treat. 2002. PMID: 12495789 Clinical Trial.
Psychological therapies for treatment-resistant depression in adults.Cochrane Database Syst Rev. 2018 May 14;5(5):CD010558. doi: 10.1002/14651858.CD010558.pub2. Cochrane Database Syst Rev. 2018. PMID: 29761488 Free PMC article. Review.
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.Front Pharmacol. 2018 Jul 5;9:733. doi: 10.3389/fphar.2018.00733. eCollection 2018. Front Pharmacol. 2018. PMID: 30026698 Free PMC article.
Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?J Psychopharmacol. 2015 Mar;29(3):241-53. doi: 10.1177/0269881114568040. Epub 2015 Feb 9. J Psychopharmacol. 2015. PMID: 25670401 Review.